Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation COVID-19, Profession, Business Practice

The Pandemic Diaries

Throughout 2020, we have been asking medicine makers from around the world to tell us about their experience of COVID-19 and the impact the pandemic has had on their professional and personal lives. Here is a selection of the pandemic diaries we have published so far.

Would you like to share your own perspective on COVID-19? Email [email protected]

Featuring Mike Grippo (Catalent Pharma Solutions), Andy Lane (The Native Antigen Company), Adrian Wildfire (formerly SGS; now hVIVO)

“I remember when reports of a novel coronavirus first began to emerge in late December. Somebody mentioned it at the weekly product development meeting – more as a curiosity than anything else.”

Featuring Simon Tyler (CatSci), Nick Shackley (Johnson Matthey), Chris Lowe at (Horizon Discovery), and Andrew Bulpin (Merck)

“I’ve been humbled to observe, amongst the obvious heroism of front-line workers, the motivation of dedicated scientists who are continuing to undertake pharmaceutical R&D in the knowledge that it will one day contribute to the better treatment of, or help to defeat, the world’s evolving healthcare challenges.”

Featuring Tony O’Sullivan (ChargePoint Technology), Will Downie (Vectura), Andy Chaloner (Stream Bio) Stephane Argivier, (MIP Diagnostics) and Edward Haeggström, (Nanoform)

“As a population, we are currently learning how to function during a pandemic. Everyone is claiming “business as usual” – but can this really be the case when there are still restrictions on global travel and social distancing?”

Featuring Zahid Tharia (Pistoia Alliance), David Underwood (Quanticate), Kenneth Lee (GenScript ProBio), Mike Jagielski (KCR), Ger Brophy (Avantor)

“Over the last few months, remote working has been implemented relatively smoothly across the industry. Even before the pandemic, we’d already seen many companies embracing digital and virtual technologies within the laboratory setting through our Lab of the Future (LotF) initiatives, and this has now picked up further pace.”

Featuring Erik Haeffler (Recipharm), Don O’Callaghan (West Pharmaceutical Services, Amélie Boulais (Sartorius)

“Despite the underlying competitive spirit among biopharma companies to be the first to create a vaccine, I believe this pandemic demonstrates the importance of collaboration among different industry members.”

Featuring Editorial staff from Texere Publishing: Stephanie Sutton, Rich Whitworth, and Michael Schubert

“SARS-CoV-19 – or rather its devastating direct and indirect effects – certainly never crossed my worried mind in 2019 (despite subconsciously knowing that the risk was always there; if SARS and MERS weren’t warning shots across the bow, I don’t know what were).”

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine